Related Experiment Video

Updated: May 24, 2026

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

In vivo selection of moxifloxacin-resistant Clostridium difficile

Ana Mena, Elena Riera, Carla López-Causapé

    Antimicrobial Agents and Chemotherapy
    |February 29, 2012
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
    12:58

    A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

    Published on: May 25, 2017

    Related Experiment Videos

    Last Updated: May 24, 2026

    Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
    06:51

    Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

    Published on: December 10, 2016

    A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
    12:58

    A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

    Published on: May 25, 2017

    Related Concept Videos

    Antibiotic Selection00:57

    Antibiotic Selection

    Overview
    Development of Antibiotic Resistance01:30

    Development of Antibiotic Resistance

    Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
    Mechanism of Antibiotic Resistance in MRSA01:25

    Mechanism of Antibiotic Resistance in MRSA

    Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...

    Articles linked to this work by shared authors, journal, and citation graph.

    Comparison of Galleria mellonella, epithelial cell cytotoxicity, and mouse model of bacteremia to measure Pseudomonas aeruginosa virulence.

    Infection and immunity·2026

    In vivo emergence of ceftazidime/avibactam resistance in Pseudomonas aeruginosa driven by OXA-1381, a novel W157L Ω-loop variant of OXA-2.

    Antimicrobial agents and chemotherapy·2026

    Natural and synthetic chemicals acting as enhancers of bacterial pathogenic success within the human host.

    Frontiers in cellular and infection microbiology·2026

    Dual β-lactam therapy against high-risk Pseudomonas aeruginosa isolates: a dynamic in-vitro infection model study integrating population genomics with quantitative systems pharmacology modelling and simulations.

    The Lancet. Microbe·2026

    Characterizing the V516M penicillin-binding protein 2 (PBP2) mutation causing zidebactam resistance in Pseudomonas aeruginosa.

    Antimicrobial agents and chemotherapy·2026

    Genetic and biochemical characterization of OXA-1054, a carbapenem-hydrolyzing class D β-lactamase conferring broad-spectrum β-lactam resistance in Pseudomonas aeruginosa.

    Antimicrobial agents and chemotherapy·2026

    L2 β-lactamase contributes to ceftolozane-tazobactam resistance in Pseudomonas aeruginosa.

    Antimicrobial agents and chemotherapy·2026

    Safety and pharmacokinetics of CL-197, a potent compound with low cytotoxicity against HIV-1: a randomized, double-blind, placebo-controlled, first-in-human phase 1 clinical trial.

    Antimicrobial agents and chemotherapy·2026

    Phage-first treatment results in subpopulation-driven collateral sensitivity to beta-lactams in an extensively drug-resistant Pseudomonas aeruginosa.

    Antimicrobial agents and chemotherapy·2026

    Population pharmacokinetics of piperacillin/tazobactam in critically ill pediatric patients.

    Antimicrobial agents and chemotherapy·2026

    XAB06, a glyco-humanized broad-spectrum anti-Pseudomonas aeruginosa polyclonal antibody, protects mice in a lethal sepsis model.

    Antimicrobial agents and chemotherapy·2026

    In vitro activity profiles and temporal trends in reduced susceptibility to azoles in Coccidioides in the United States.

    Antimicrobial agents and chemotherapy·2026

    Incidence of post-operative infections and antibiotic resistance trends: A clinical study.

    Bioinformation·2026

    From Symbiont to Potential Carcinogenic Contributor: Examining the Pathogenic Evolution of Morganella morganii in Colorectal Cancer.

    Infection and drug resistance·2026

    Spatially and temporally resolved assessment of quantitative skeletal muscle perfusion with non-contrast MRI in patients with PAD and healthy controls.

    Quantitative imaging in medicine and surgery·2026

    Pharmacist-coordinated IDST treatment bundle achievement and impact on mortality in MRSA bacteraemia: a single-centre retrospective cohort study.

    Infection prevention in practice·2026

    Four-year surveillance of major Gram-negative pathogens in a Saudi tertiary hospital: clinical distribution, comorbidity profiles, and antimicrobial resistance.

    Expert review of anti-infective therapy·2026

    "One Health"-based epidemiological investigation reveals the emergence of carbapenem-resistant Morganella spp. across diverse ecological niches.

    Journal of global antimicrobial resistance·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us